The Management Board also includes: Dr. Liane Bauer (Abbott), Dr. Anika Jöcker (Cepheid), Dr. Anette Leue (Promega), Dr. Maxime Ndolumingo (bioMérieux), Dr. Matthias Probst (QIAGEN) and Ulrich Schmid (A. Menarini Diagnostics).
Signal to politicians: act now
With regard to politics, the new VDGH Chairman welcomes the fact that the industrial healthcare sector is to be strengthened as a leading economy. This promise in the coalition agreement must now be followed by targeted measures to set the course for modern and efficient healthcare. "We need a national MedTech strategy that is cross-departmental and promotes innovation in a targeted manner," emphasizes Schüßler. The government declaration by Federal Chancellor Friedrich Merz has provided initial important impetus - now it is a matter of implementation.
"We welcome the clear commitment to competitiveness and the promotion of modern technologies," continued Schüßler. "Now we need decisive measures that will really give the healthcare industry and Germany as a business location a tailwind." The VDGH has presented concrete proposals for this and is ready for a joint dialog with politicians and healthcare partners.
Prof. Josef Hecken at the VDGH theme evening
On the eve of the VDGH General Assembly, the focus was on dialog with the joint self-administration. Prof. Josef Hecken, impartial chairman of the Federal Joint Committee (G-BA), spoke to a packed hall in the Rhineland-Palatinate state representation about the challenges facing the healthcare system and possible reform approaches under the title "Healthcare of the future - what course is important now?". Hecken emphasized the role of precise diagnostics for effective care management and underlined the importance of actively shaping cross-sector structures. "Diagnostics is a key to modern care - from prevention to personalized therapy," said Prof. Hecken.
